Allele Biotech to Partner with UC San Diego on ARPA-H Project to End Liver Transplant Shortage with 3D Bioprinting
Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing company, today announced its participation in an up to $25.8 million research project with the University of California, San Diego, funded by the Advanced Research Projects Agency for Health (ARPA-H). The project’s goal is to develop a fully functional, patient-specific, 3D bioprinted liver for transplantation. This project is under ARPA-H’s Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program which intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on demand organs that do not require immunosuppressive drugs. The PRINT program is led by ARPA-H Program Manager Ryan Spitler, Ph.D.
